LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

Kodu・Aktsiate loetelu・Cogent Biosciences Inc

Cogent Biosciences Inc

Suletud

39.63 0.08

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

39.54

Max

40.16

Põhinäitajad
By Trading Economics
Sissetulek	-7.4M -81M
Aktsiakasum	-0.5
Kasumimarginaal	-1,582.642
Töötajad	205
EBITDA	-6.8M -79M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+17.55% upside

Turustatistika
By TradingEconomics
Turukapital	3.9B 6B
Eelmine avamishind	39.55
Eelmine sulgemishind	39.63

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

4.88 / 5.87 Toetus ja vastupanu

Cogent Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. dets 2025, 21:41 UTC

Omandamised, ülevõtmised, äriostud

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

24. dets 2025, 14:57 UTC

Omandamised, ülevõtmised, äriostud

Accenture to Acquire Cabel Industry from Fibonacci Group

25. dets 2025, 23:42 UTC

Market Talk

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25. dets 2025, 23:40 UTC

Market Talk

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25. dets 2025, 00:20 UTC

Omandamised, ülevõtmised, äriostud

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24. dets 2025, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24. dets 2025, 21:26 UTC

Omandamised, ülevõtmised, äriostud

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24. dets 2025, 19:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. dets 2025, 19:35 UTC

Market Talk

Treasury Yields Decline Ahead of Christmas -- Market Talk

24. dets 2025, 19:09 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

24. dets 2025, 19:09 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24. dets 2025, 19:06 UTC

Market Talk

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

24. dets 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Futures Give Back Some Gains -- Market Talk

24. dets 2025, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

24. dets 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

24. dets 2025, 17:08 UTC

Omandamised, ülevõtmised, äriostud

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24. dets 2025, 16:53 UTC

Omandamised, ülevõtmised, äriostud

Nike Climb Boosts Dow, S&P 500 -- WSJ

24. dets 2025, 16:31 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

ServiceNow Gets Top-Tier Asset and Talent With Armis Buy -- Market Talk

24. dets 2025, 16:28 UTC

Omandamised, ülevõtmised, äriostud

Lam Research Is at All-Time Highs. Its CEO Just Sold $27 Million Worth of Stock. -- Barrons.com

24. dets 2025, 16:17 UTC

Market Talk

Dollar Stable as U.S. Layoffs Remain at Bay -- Market Talk

24. dets 2025, 15:33 UTC

Omandamised, ülevõtmised, äriostud

Nike Shares Get a Lift After Apple's Tim Cook Doubles His Personal Stake -- WSJ

24. dets 2025, 15:30 UTC

Omandamised, ülevõtmised, äriostud

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24. dets 2025, 15:19 UTC

Omandamised, ülevõtmised, äriostud

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24. dets 2025, 14:49 UTC

Omandamised, ülevõtmised, äriostud

Mexico's Ollamani Sells Stake in Azteca Stadium

24. dets 2025, 14:19 UTC

Market Talk

U.S. Natural Gas Futures Move Lower After Big Jump -- Market Talk

24. dets 2025, 14:08 UTC

Omandamised, ülevõtmised, äriostud

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24. dets 2025, 14:06 UTC

Market Talk

Oil Futures Edge Up on Geopolitical Risk Premium -- Market Talk

24. dets 2025, 13:24 UTC

Market Talk

Canada's Economy Needs More Help Amid Dismal GDP Report -- Market Talk

24. dets 2025, 12:59 UTC

Omandamised, ülevõtmised, äriostud

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24. dets 2025, 12:51 UTC

Omandamised, ülevõtmised, äriostud

Disney Could Be the Real Winner from the Warner Takeover Battle. Here's Why. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Cogent Biosciences Inc Prognoos

Hinnasiht

By TipRanks

17.55% tõus

12 kuu keskmine prognoos

Keskmine 47.22 USD 17.55%

Kõrge 67 USD

Madal 34 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Cogent Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Cogent Biosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

4.88 / 5.87Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.